Skip to main content

Advertisement

Log in

S-adenosyl-methionine in depression: A comprehensive review of the literature

Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

As many as 29% to 46% of patients with major depressive disorder (MDD) show only partial or no response to an adequate course of an antidepressant. The current practice is to increase the dose, switch to another antidepressant, or to combine the initial antidepressant with an antidepressant of a different class or a non-antidepressant agent. A growing number of studies have also been directed toward exploring the potential use of augmenting traditional antidepressants with nonpharmaceutic supplements, or even using such supplements as monotherapy for depression. S-adenosyl-methionine (SAMe) is one such compound. Compared with many other nonpharmaceutic supplements, SAMe has been extensively studied, and impressive literature extending back three decades suggests the antidepressant efficacy of SAMe. In the present work, the authors summarize the literature, focusing on the potential role of SAMe and its precursors in the pathophysiology of MDD, followed by a review of studies examining the use of SAMe for the treatment of MDD. Finally, the authors propose a model that would explain the actions of SAMe in the central nervous system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Bottiglieri T, Hyland K: S-adenosylmethionine in psychiatric and neurological disorders: a review. Acta Neurol Scand 1994, 154:19–26.

    CAS  Google Scholar 

  2. Bottiglieri T: S-adenosyl-L-methionine (SAMe): from the bench to the bedside-molecular basis of a pleiotropic molecule. Am J Clin Nutr 2002, 75(suppl):1151S-1157S.

    Google Scholar 

  3. Baldessarini RJ: The neuropharmacology of S-adenosyl-Lmethionine. Am J Med 1987, 83:95–103.

    Article  PubMed  CAS  Google Scholar 

  4. Cestaro B: Effects of arginine, s-adenosylmethionine and polyamines on nerve regeneration. Acta Neurol Scand 1994, 154:32–41.

    CAS  Google Scholar 

  5. Bottiglieri T, Laundry M, Crellin R, et al.: Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000, 69:228–232.

    Article  PubMed  CAS  Google Scholar 

  6. Bottiglieri T, Chary CK, Laundy M, et al.: Transmethylation in depression. Ala J Med Sci 1988, 25:296–301.

    PubMed  CAS  Google Scholar 

  7. Bottiglieri T, Godfrey P, Flynn T, et al.: Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatr 1990, 53:1096–1098.

    PubMed  CAS  Google Scholar 

  8. Tolbert LC, Monti JA, O’Shields H: Defects in transmethylation and membrane lipids in schizophrenia. Psychopharmacol Bull 1983, 19:594–599.

    CAS  Google Scholar 

  9. Smythies JR, Alarcon RD, Bancroft AJ: Role of the one-carbon cycle in neuropsychiatry. In Biological Methylation and Drug Design. Edited by Borchardt R, Creveling C, Ueland P. Clifton: Humana Press; 1986.

    Google Scholar 

  10. Arinami T, Yamada N, Yamakawa-Kobayashi K, et al.: Methylenetetrahydrofolate reductase variant and schizophrenia/ depression. Am J Med Gen 1997, 74:526–528.

    Article  CAS  Google Scholar 

  11. Hickie I, Scott E, Naismith S, et al.: Late-onset depression: genetic, vascular and clinical contributions. Psychol Med 2001, 31:1403–1412.

    Article  PubMed  CAS  Google Scholar 

  12. Bjelland I, Tell GS, Vollset SE, et al.: Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 2003, 60:618–626.

    Article  PubMed  CAS  Google Scholar 

  13. Hector M, Burton JR: What are the psychiatric manifestations of vitamin B12 deficiency? J Am Geriatr Soc 1988, 36:1105–1112.

    PubMed  CAS  Google Scholar 

  14. Tiemeier H, Van Tuijl HR, Hofman A, et al.: Vitamin B(12), folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002, 159:2099–2101.

    Article  PubMed  Google Scholar 

  15. Levitt AJ, Joffe RT: Folate, B12, and thyroid function in depression. Biol Psychiatry 1993, 33:52–53.

    Article  PubMed  CAS  Google Scholar 

  16. Bell IR, Edman JS, Morrow FD, et al.: B complex vitamin patterns in geriatric and young adult inpatients with major depression. JAGS 1991, 39:252–257.

    CAS  Google Scholar 

  17. Bottiglieri T, Hyland K, Laundry M, et al.: Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med 1992, 22:871–876.

    PubMed  CAS  Google Scholar 

  18. Abou-Saleh MT, Coppen A: Serum and red blood cell folate in depression. Acta Psychiatr Scand 1989, 80:78–82.

    PubMed  CAS  Google Scholar 

  19. Carney MW, Sheffield BF: Serum folic acid and B12 in 272 psychiatric in-patients. Psychol Med 1978, 8:139–144.

    Article  PubMed  CAS  Google Scholar 

  20. Carney MWP, Chary TKN, Laundy M, et al.: Red cell folate concentrations in psychiatric inpatients. J Affect Disord 1990, 19:207–213.

    Article  PubMed  CAS  Google Scholar 

  21. Lee S, Wing YK, Fong S: A controlled study of folate levels in Chinese inpatients with major depression in Hong Kong. J Affect Disord 1998, 49:73–77.

    Article  PubMed  CAS  Google Scholar 

  22. Ghadirian AM, Anath J, Engelsman F: Folic acid deficiency in depression. Psychosomatics 1980, 21:926–929.

    PubMed  CAS  Google Scholar 

  23. Wilkinson Am, Anderson DN, Abou-Saleh MT, et al.: 5_methyltetrahydrofolate level in the serum of depressed subjects and its relationship to the outcome of ECT. J Affect Disord 1994, 32:163–168.

    Article  PubMed  CAS  Google Scholar 

  24. Fava M, Borus JS, Alpert JE, et al.: Folate, B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997, 154:426–428.

    PubMed  CAS  Google Scholar 

  25. Morris MS, Fava M, Jacques PF, et al.: Depression and folate status in the US population. Psychother Psychosom 2003, 72:80–87.

    Article  PubMed  Google Scholar 

  26. Wesson VA, Levitt AJ, Joffe RT: Change in folate status with antidepressant treatment. Psychiatry Res 1994, 53:313–322.

    Article  PubMed  CAS  Google Scholar 

  27. Bell IR, Edman J, Marby DW, et al.: Vitamin B12 and folate status in acute geropsychiatric inpatients: affective and cognitive characteristics of a vitamin non-deficient population. Biol Psychiatry 1990, 27:125–137.

    Article  PubMed  CAS  Google Scholar 

  28. Alpert M, Silva RR, Pouget ER: Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol 2003, 23:309–313.

    Article  PubMed  CAS  Google Scholar 

  29. Levitt AJ, Wesson VA, Joffe RT: Impact of suppression of thyroxine on folate status during acute antidepressant therapy. Psychiatry Res 1998, 79:123–129.

    Article  PubMed  CAS  Google Scholar 

  30. Coppen A, Bailey J: Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. J Affect Disord 2000, 60:121–130. This is a study examining the double-blind, co-initiation of folate versus placebo with fluoxetine during the acute-phase (10 weeks) of pharmacotherapy for MDD (n=127). The authors found that fluoxetine plus folate was more effective in alleviating depressive symptoms in women than fluoxetine plus placebo.

    Article  PubMed  CAS  Google Scholar 

  31. Reynolds EH, Preece JM, Bailey J, Coppen A: Folate deficiency in depressive illness. Br J Psychiatry 1970, 117:287–292.

    PubMed  CAS  Google Scholar 

  32. Godfrey PSA, Toone BK, Carney MWP, et al.: Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990, 36:392–395.

    Article  Google Scholar 

  33. Guarardi G, Fava M, Mazzi F, LaGreca P: An open trial of methyltetrahydrofolate (MTHF) in elderly depressed patients. Ann Clin Psychiatry 1993, 5:101–106.

    Google Scholar 

  34. Alpert JE, Mischoulon D, Rubenstein GE, et al.: Folinic acid as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry 2002, 14:33–38. This is an open trial of folinic acid (leukovorin), which is metabolized to methylfolate, as an adjunct treatment to SSRIs in SSRI-resistant depression. Of all patients enrolled (n=22), more than one-in-four SSRI-resistant patients responded by the end of the 8-week trial.

    Article  PubMed  Google Scholar 

  35. Coppen A, Chaudhry S, Swade C: Folic acid enhances lithium prophylaxis. J Affect Disord 1986, 10:9–13.

    Article  PubMed  CAS  Google Scholar 

  36. Agency for Healthcare Research Quality (AHRQ): S-sdenosyl-lmethionine for treatment of depression, osteoarthritis, and liver disease. http://www.ahrq.org/clinic/evrptfiles.htm#same.

  37. Bressa GM: S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 1994, 154:7–14.

    PubMed  CAS  Google Scholar 

  38. Pinzello A, Andreoli V: Le transmetilazioni SAM-dipendenti nelle sindromi depressive. Valutazione dell-effetto terapeutico della S-adenosilmetionina con la scala di Hamilton. Quad Ter Sper Suppl Bioch Biol Sper 1972, 2:3–11.

    Google Scholar 

  39. Fazio C, Andreoli V, Agnoli A, et al.: Effetti terapeutici e meccanismo d’azione della S-adenosil-l-metionina (SAMe) nelle sindromi depressive. Minerva Med 1973, 64:1515–1529.

    PubMed  CAS  Google Scholar 

  40. Agnoli A, Fazio C, Andreoli V: Disturbi neuropsichiatrici e transmetilazioni. Effetti terapeutici della S adenosil-lmetionina. Clin Ter 1975, 75:567–579.

    PubMed  CAS  Google Scholar 

  41. Mantero M, Pastorino P: Sindromi depressive, malattie cutanee e transmetilazioni. Effetti terapeutici della s-adenosyl-lmetionina. Gazz Med Ital 1976, 135:707–716.

    Google Scholar 

  42. Andreoli V, Campedelli A, Maffei F: La s-adenosil-l-metionina (SAMe) in geropsichiatria: uno studio clinico controllato “in aperto” nelle sindromi depressive dell’eta’ senile. G Gerontol 1977, 25:172–180.

    Google Scholar 

  43. Barberi A, Pusateri C: Sugli effetti clinici della s-adenosil-lmetionina (SAMe) nelle sindromi depressive. Minerva Psichiatr 1978, 19:235–243.

    Google Scholar 

  44. Salvadorini F, Galeone F, Saba P, et al.: Evaluation of s-adenosylmethionine (SAMe) effectiveness on depression. Curr Ther Res 1980, 27:908–918.

    Google Scholar 

  45. Carney MW, Edeh J, Bottiglieri T, et al.: Affective illness and s-adenosylmethionine: a preliminary report. Clin Neuropharmacol 1986, 9:379–385.

    Article  PubMed  CAS  Google Scholar 

  46. Lipinski JF, Cohen BM, Frankenburg F, et al.: An open trial of S-adenosylmethionine for treatment of depression. Am J Psychiatry 1984, 141:448–450.

    PubMed  CAS  Google Scholar 

  47. Fava M, Gianelli A, Rapisarda V, et al.: Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res 1995, 56:295–297.

    Article  PubMed  CAS  Google Scholar 

  48. Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H: Efficacy of s-adenosyl-l-methionine in speeding the onset of action of imipramine. Psychiatry Res 1992, 44:257–262.

    Article  PubMed  CAS  Google Scholar 

  49. Bell KM, Plon L, Bunney WE Jr., Potkin SG: S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry 1988, 145:1110–1114.

    PubMed  CAS  Google Scholar 

  50. Janicak PG, Lipinski J, Davis JM, et al.: S-adenosylmethionine in depression: a literature review and preliminary report. Ala J Med Sci 1988, 25:306–313.

    PubMed  CAS  Google Scholar 

  51. Delle Chiaie R, Pancheri P, Scapicchio P: Efficacy and tolerability of oral and intramuscular S-adenosyl-l-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr 2002, 76(suppl):1172S-1176S. This recent report focuses on presenting data from two double-blind MDD acute treatment trials; the first was a 6-week trial of oral SAMe versus oral imipramine (n=281), the second was a 4-week trial of intramuscular SAMe versus oral imipramine (n=295) The authors found that oral and intramuscular SAMe equally as effective as imipramine.

    PubMed  CAS  Google Scholar 

  52. Pancheri P, Scapicchio P, Chiaie RD: A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol 2002, 5:287–294.

    Article  PubMed  CAS  Google Scholar 

  53. Caruso I, Fumagalli M, Boccassini L, et al.: Antidepressant activity of S-adenosyl-methionine. Lancet 1984, I:904.

    Article  Google Scholar 

  54. Loehrer FM, Schwab R, Angst CP, et al.: Influence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine and methionine in healthy humans. J Pharmacol Exp Ther 1997, 282:845–850.

    PubMed  CAS  Google Scholar 

  55. Iruela LM, Minguez L, Merino J, Monedero G: Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993, 150:522.

    PubMed  CAS  Google Scholar 

  56. Castagna A, Le Grazie C, Accordini A: Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAMe. Neurology 1995, 45:1678–1683.

    PubMed  CAS  Google Scholar 

  57. Rosenbaum JF, Fava M, Falk WE, et al.: The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand 1990, 81:432–436.

    PubMed  CAS  Google Scholar 

  58. Fava M, Rosenbaum JF, MacLaughlin R, et al.: Neuroendocrine effects of s-adenosyl-l-methionine, a novel putative antidepressant. J Psychiatric Res 1990, 24:177–184.

    Article  CAS  Google Scholar 

  59. Fava M, Rosenbaum JF, Birnbaum R, et al.: The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand 1992, 86:42–45.

    PubMed  CAS  Google Scholar 

  60. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH: Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 1990, 147:591–595.

    PubMed  CAS  Google Scholar 

  61. Salmaggi P, Bressa GM, Nicchia G, et al.: Double-blind, placebo-controlled study of s-adenosyl-l-methionine in depressed post-menopausal women. Psychother Psychosom 1993, 59:34–40.

    Article  PubMed  CAS  Google Scholar 

  62. Bell MB, Carreon D, Plon L, et al.: Oral s-adenosylmethionine in the treatment of depression: a double-blind comparison with desipramine. Study report. BioResearch File 1990.

  63. De Vanna M, Rigamonti R: Oral S-adenosyl-L-methionine in depression. Curr Ther Res 1992, 52:478–485.

    Article  Google Scholar 

  64. Greenberg RP, Bornstein RF, Greenberg MD, Fisher S: A metaanalysis of antidepressant outcome under “blinder” conditions. J Consult Clin Psychol 1992, 5:664–669.

    Google Scholar 

  65. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56–62.

    Article  PubMed  CAS  Google Scholar 

  66. Scott JM, Molloy AM, Kennedy DG, et al.: Effects of the disruption of transmethylation in the central nervous system: an animal model. Acta Neurol Scand 1994, 154(suppl):27–31.

    CAS  Google Scholar 

  67. Cohen BM, Satlin A, Zubenko GS: S-adenosyl-l-methionine in the treatment of Alzheimer’s disease. J Clin Psychopharmacol 1988, 8:43–47.

    PubMed  CAS  Google Scholar 

  68. Heron DS, Shinitzky M, Turnbull J, Shatill SJ: Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Procl Natl Acad Sci U S A 1980, 77:7463–7467.

    Article  CAS  Google Scholar 

  69. Hirata F, Axelrod J: Phospholipid methylation and biological signal transmission. Science 1980, 209:1082–1090.

    Article  PubMed  CAS  Google Scholar 

  70. Crews FT: Effects of membrane fluidity on secretion and receptor stimulation. Psychopharmacol Bull 1982, 18:135–143.

    PubMed  CAS  Google Scholar 

  71. Becher A, White J, McIlhinney R, Jeffrey RA: The [gamma]-aminobutyric acid receptor B, but not the metabotropic glutamate receptor type-1, associates with lipid rafts in the rat cerebellum. J Neurochem 2001, 79:787–795.

    Article  PubMed  CAS  Google Scholar 

  72. Ohvo-Rekika H, Ramtedt B, Leppimaki P, Slotte P: Cholesterol interactions with phospholipids in membranes. Prog Lipid Res 2002, 41:66–97.

    Article  Google Scholar 

  73. Hirata F, Strittmatter WJ, Axelrod J: Beta-adrenergic receptor agonists increase phospholipid methylation, membrane fluidity, and beta-adrenergic receptor-adenylate cyclase coupling. Proc Natl Acad Sci U S A 1979, 76:368–372.

    Article  PubMed  CAS  Google Scholar 

  74. Muccioli G, Scordamaglia A, Bertacco S, Di Carlo R: Effect of S-adenosyl-l-methionine on brain muscarinic receptors of aged rats. Eur J Pharmacol 1992, 227:293–299.

    Article  PubMed  CAS  Google Scholar 

  75. Pavia J, Martos F, Gonzalez-Correa JA, et al.: Effect of S-adenosyl methionine on muscarinic receptors in young rats. Life Sci 1997, 60:825–832.

    Article  PubMed  CAS  Google Scholar 

  76. Muccioli G, Di Carlo R: Adenosyl-l-methionine restores prolactin receptors in the aged rabbit brain. Eur J Pharmacol 1989, 166:223–230.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Papakostas, G.I., Alpert, J.E. & Fava, M. S-adenosyl-methionine in depression: A comprehensive review of the literature. Curr Psychiatry Rep 5, 460–466 (2003). https://doi.org/10.1007/s11920-003-0085-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-003-0085-2

Keywords

Navigation